NCT07274020

Long-Term Safety and Efficacy of Moxifloxacin in Bronchiectasis Patients

Effectiveness and Safety of Long-Term Intermittent Moxifloxacin Eradication Therapy in Non-Cystic Fibrosis Bronchiectasis: A 12-Month Randomized Controlled Trial

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 140 (estimated)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Bronchiectasis is a chronic respiratory disease characterized by recurrent infections, inflammation, and progressive lung damage. Frequent exacerbations are associated with increased morbidity, accelerated lung function decline, and reduced quality of life. Preventing exacerbations is a key therapeutic goal. Moxifloxacin, a fluoroquinolone antibiotic with broad-spectrum activity, may play a role in intermittent eradication therapy to reduce bacterial load, achieve microbiological clearance, and minimize exacerbation frequency. This randomized controlled trial will evaluate the effectiveness and safety of long-term intermittent moxifloxacin therapy compared with standard care in patients with non-cystic fibrosis bronchiectasis.

Conditions

• Bronchiectasis, Non-Cystic Fibrosis

Interventions

Type	Name	Description
DRUG	Intermittent Moxifloxacin + Standard Care	Moxifloxacin 400 mg orally once daily for 7 days every 8 weeks (total 6 cycles over 12 months), in addition to guideline-based standard care
OTHER	Standard Care (in control arm)	Participants will receive guideline-based management of bronchiectasis without long-term suppressive antibiotics.

Timeline

• Start date: 2025-12-01
• Primary completion: 2026-12-01
• Completion: 2027-01-01
• First posted: 2025-12-10
• Last updated: 2025-12-10

Locations

1 site across 1 country: Egypt